Trial Profile

A phase I trial of radioimmunotherapy (Y90 cT8.66) [anti-CEA-monoclonal-antibody-cT84-66-Y-90], gemcitabine and hepatic arterial infusion of Fudr [floxuridine] for metastatic colorectal carcinoma to the liver.

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Mar 2019 Biomarkers information updated
09 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
21 Jul 2010 Planned end date changed from 1 Sep 2012 to 1 Apr 2015 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com